These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 7118328)

  • 1. The multinational drug companies in Zaire: their adverse effect on cost and availability of essential drugs.
    Glucksberg H; Singer J
    Int J Health Serv; 1982; 12(3):381-7. PubMed ID: 7118328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zaire.
    United States. Department of State. Bureau of Public Affairs
    Backgr Notes Ser; 1988 Aug; ():1-8. PubMed ID: 12178026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sale of drugs and health care utilization in a health care district in Zaire.
    Courtois X; Dumoulin J
    Health Policy Plan; 1995 Jun; 10(2):181-6. PubMed ID: 10172351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The economics of pharmaceutical supply in Tanzania.
    Yudkin JS
    Int J Health Serv; 1980; 10(3):455-77. PubMed ID: 7419314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Provision of medicines in a developing country.
    Yudkin JS
    Lancet; 1978 Apr; 1(8068):810-2. PubMed ID: 85826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economics of essential drugs schemes: the perspectives of the developing countries.
    Wang'ombe JK; Mwabu GM
    Soc Sci Med; 1987; 25(6):625-30. PubMed ID: 3686097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceuticals imports in Tanzania: Overview of private sector market size, share, growth and projected trends to 2021.
    Wande DP; Sangeda RZ; Tibalinda P; Mutta IK; Mkumbwa S; Bitegeko A; Kaale E
    PLoS One; 2019; 14(8):e0220701. PubMed ID: 31404109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceutical companies' variation of drug prices within and among countries can improve long-term social well-being.
    Lichtenberg FR
    Health Aff (Millwood); 2011 Aug; 30(8):1539-44. PubMed ID: 21821571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An analysis of the medical supply industries.
    Turshen M
    Int J Health Serv; 1976; 6(2):271-94. PubMed ID: 939622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Public drug procurement: the lessons from a drug tender in a teaching hospital of a transition country.
    Milovanovic DR; Pavlovic R; Folic M; Jankovic SM
    Eur J Clin Pharmacol; 2004 May; 60(3):149-53. PubMed ID: 15057496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Philippines joins other developing countries in limiting prices of drugs.
    Bland B
    BMJ; 2009 Aug; 339():b3151. PubMed ID: 19651688
    [No Abstract]   [Full Text] [Related]  

  • 13. Examining the production costs of antiretroviral drugs.
    Pinheiro E; Vasan A; Kim JY; Lee E; Guimier JM; Perriens J
    AIDS; 2006 Aug; 20(13):1745-52. PubMed ID: 16931939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reprivatizing pharmaceutical supplies in Africa.
    Turshen M
    J Public Health Policy; 2001; 22(2):198-225. PubMed ID: 11469153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs for STD management in developing countries: choice, procurement, cost, and financing.
    Van der Veen F; Fransen L
    Sex Transm Infect; 1998 Jun; 74 Suppl 1():S166-74. PubMed ID: 10023369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The economics of essential drug programmes.
    Smith GT
    Soc Sci Med; 1987; 25(6):621-4. PubMed ID: 3686096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. When medicine becomes a disease.
    Arabia; 1986 Mar; 5(55):32-6. PubMed ID: 12340711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Globalization of the pharmaceutical industry and the growing dependency of developing countries: the case of Turkey.
    Semin S; Güldal D
    Int J Health Serv; 2008; 38(2):379-98. PubMed ID: 18459286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Essential and non-essential drugs marketed by the 20 largest European pharmaceutical companies in developing countries.
    Hartog R
    Soc Sci Med; 1993 Oct; 37(7):897-904. PubMed ID: 8211308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential pricing of new pharmaceuticals in lower income European countries.
    Kaló Z; Annemans L; Garrison LP
    Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):735-41. PubMed ID: 24219049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.